The over USD 70 million plant has been designed to meet the world’s most stringent regulatory standards. It sits on 12 acres of land located 12km east of Kampala- Uganda and has a built up area of 14,000 square meters.
The facility manufactures 80 million tablets a month and plans are underway to increase its production capacity. The facility produces complex molecules of various fixed dose medicines for the management of malaria and HIV/AIDS.
The goal of the design specifications for CiplaQCIL is to produce pharmaceutical products of the highest quality that have zero environmental impact, adhere to current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP), all consistent with global, regional and local regulatory standards.
The plant and medicines produced at CiplaQCIL have been approved by: